Prostate‐specific antigen velocity (PSAV) risk count improves the specificity of screening for clinically significant prostate cancer

Study Type – Prognosis (retrospective cohort analysis)

[1]  J. Gohagan,et al.  Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. , 2012, Journal of the National Cancer Institute.

[2]  E. Metter,et al.  What is the true number needed to screen and treat to save a life with prostate-specific antigen testing? , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Erik Holmberg,et al.  Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. , 2010, The Lancet. Oncology.

[4]  B. G. Blijenberg,et al.  Screening and prostate-cancer mortality in a randomized European study. , 2009, The New England journal of medicine.

[5]  Monique J. Roobol,et al.  Re: Mortality Results from a Randomized Prostate-Cancer Screening Trial , 2009 .

[6]  M. Roobol,et al.  Is prostate-specific antigen velocity selective for clinically significant prostate cancer in screening? European Randomized Study of Screening for Prostate Cancer (Rotterdam). , 2009, European urology.

[7]  Andrew J Vickers,et al.  Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Wadih Arap,et al.  Quality of life and satisfaction with outcome among prostate-cancer survivors. , 2008, The New England journal of medicine.

[9]  John T. Wei,et al.  Quality of life and satisfaction with outcome among prostate-cancer survivors. , 2008, The New England journal of medicine.

[10]  D. Ekwueme,et al.  Use of the Prostate-Specific Antigen Test among U.S. Men: Findings from the 2005 National Health Interview Survey , 2008, Cancer Epidemiology Biomarkers & Prevention.

[11]  M. Pencina,et al.  Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond , 2008, Statistics in medicine.

[12]  F. Bray,et al.  Interpreting trends in prostate cancer incidence and mortality in the five Nordic countries. , 2007, Journal of the National Cancer Institute.

[13]  W. Catalona,et al.  Prostate specific antigen velocity in men with total prostate specific antigen less than 4 ng/ml. , 2007, The Journal of urology.

[14]  L. Ferrucci,et al.  Prostate-specific antigen velocity risk count assessment: a new concept for detection of life-threatening prostate cancer during window of curability. , 2007, Urology.

[15]  N. Cook.  Use and Misuse of the Receiver Operating Characteristic Curve in Risk Prediction , 2007, Circulation.

[16]  John T. Wei,et al.  Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. , 2006, Journal of the National Cancer Institute.

[17]  L. Ferrucci,et al.  Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. , 2006, Journal of the National Cancer Institute.

[18]  W. Catalona,et al.  Survival results in patients with screen-detected prostate cancer versus physician-referred patients treated with radical prostatectomy: early results. , 2006, Urologic oncology.

[19]  M. Barry,et al.  Brief report: Physicians and their personal prostate cancer-screening practices with prostate-specific antigen , 2006, Journal of General Internal Medicine.

[20]  L. Klotz.  Active surveillance for prostate cancer: for whom? , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  A. Renshaw,et al.  Adult urologyUrological survey: urological oncology: prostate cancerPretreatment PSA Velocity and Risk of Death From Prostate Cancer Following External Beam Radiation Therapy , 2006 .

[22]  P. Walsh,et al.  Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. , 2005, The Journal of urology.

[23]  J. Crowley,et al.  Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. , 2004, The New England journal of medicine.

[24]  William J Catalona,et al.  Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. , 2003, The New England journal of medicine.

[25]  Lisa M. Schwartz,et al.  Screening men for prostate and colorectal cancer in the United States: does practice reflect the evidence? , 2003, JAMA.

[26]  W. Catalona,et al.  Rate of change in serum prostate specific antigen levels as a method for prostate cancer detection. , 1994, The Journal of urology.

[27]  D. Brizel,et al.  National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology , 2012 .

[28]  K. Markou,et al.  National Comprehensive Cancer Network (NCCN) Head and Neck Cancers NCCN Clinical Practice Guidelines in Oncology . 2010. , 2011 .

[29]  W. Catalona,et al.  Can prostate specific antigen velocity thresholds decrease insignificant prostate cancer detection? , 2010, The Journal of urology.

[30]  Herbert Lepor,et al.  Radical prostatectomy with preservation of sexual function: Anatomical and pathological considerations , 1983, The Prostate.